Ann: June Quarterly Activity and Cashflow Report, page-7

30 July 2018 ASX Code: MXC June 2018 Quarterly Activity Report
 Significant milestones achieved in the June 2018 quarter
 MGC Pharma: GMP Certification and Manufacturing Licence awarded to European production and manufacturing facility, which is now one of the most sophisticated in Europe
- Immediate production of CannEpilTM can now commence
 MGC Pharma: MXC granted the first full medical cannabis cultivation and production agreement in Malta, to construct the facility on designated land
 MGC Botanic: Delivers first milestone, with CBD extracted from first Czech Republic harvest manufactured into MXC products under seed-to-sale operations
 MGC Derma: Launched its second Derma Plus product – its CBD Herbal Replenish Cream - and signed a supply agreement with luxury retailer Harvey Nichols
 Corporate: Completed $5m oversubscribed placement in April 2018 to help the establishment of the medical cannabis cultivation and production facility in Malta and for general working capital
 MXC’s Scientific Advisory Board will present at the Cannapaed Symposium 2019 conference, for carers of children with Epilepsy and other serious neurological disorders. The conference is set to educate the UK and European markets about cannabis based neurological medicines
Pharmaceuticals Ltd (ASX: MXC or “the Company”) has today published its Appendix 4C for the three-month period to 30 June 2018 and is pleased to provide a review of the progress made during the quarter
Operational Update
During the quarter, the Company delivered strong progress across all divisions and especially within the MGC Pharma division, where a major milestone was completed on receiving the final GMP certificate and manufacturing licence for its European facility.